BACKGROUND: The study aimed to determine the incidence of K-ras and BRAF mutations in colorectal cancers (CRCs) in Thai patients and evaluate association with clinicopathological parameters including treatment outcomes in terms of event free survival (EFS). MATERIALS AND METHODS: Two-hundred colorectal cancer specimens were collected for studies of K-Ras codon 12, 13 and 61, and BRAF codon 600 by polymerase chain reaction and direct nucleotide sequencing. RESULTS: The overall incidence of K-Ras mutations in our patients was 23%. K-ras mutation frequencies in CRC stages (AJCC) I, II, III and IV were 6.7%, 16.1%, 23.3% and 26.6%, respectively (p-value>0.05). The three most common mutation forms were G12D, G12V and G13D. K-Ras mutation status was associated with poorer EFS in stage I-III CRCs (p-value 0.03). CONCLUSIONS: The study found a lower mutation frequency of K-Ras and BRAF compared to reports involving other ethnic groups. However, K-Ras mutations did have a negative prognostic value in early-stage CRCs.
BACKGROUND: The study aimed to determine the incidence of K-ras and BRAF mutations in colorectal cancers (CRCs) in Thai patients and evaluate association with clinicopathological parameters including treatment outcomes in terms of event free survival (EFS). MATERIALS AND METHODS: Two-hundred colorectal cancer specimens were collected for studies of K-Ras codon 12, 13 and 61, and BRAF codon 600 by polymerase chain reaction and direct nucleotide sequencing. RESULTS: The overall incidence of K-Ras mutations in our patients was 23%. K-ras mutation frequencies in CRC stages (AJCC) I, II, III and IV were 6.7%, 16.1%, 23.3% and 26.6%, respectively (p-value>0.05). The three most common mutation forms were G12D, G12V and G13D. K-Ras mutation status was associated with poorer EFS in stage I-III CRCs (p-value 0.03). CONCLUSIONS: The study found a lower mutation frequency of K-Ras and BRAF compared to reports involving other ethnic groups. However, K-Ras mutations did have a negative prognostic value in early-stage CRCs.
Authors: Michael Levi; Gintang Prayogi; Farid Sastranagara; Edi Sudianto; Grace Widjajahakim; Winiarti Gani; Albert Mahanadi; Jocelyn Agnes; Bela Haifa Khairunisa; Ahmad R Utomo Journal: J Gastrointest Cancer Date: 2018-06
Authors: Lee Cheng Phua; Hui Wen Ng; Angie Hui Ling Yeo; Elya Chen; Michelle Shu Mei Lo; Peh Yean Cheah; Eric Chun Yong Chan; Poh Koon Koh; Han Kiat Ho Journal: Oncol Lett Date: 2015-08-03 Impact factor: 2.967
Authors: M J Alvarez-Cubero; L J Martinez-Gonzalez; I Robles-Fernandez; J Martinez-Herrera; G Garcia-Rodriguez; M Pascual-Geler; J M Cozar; J A Lorente Journal: Mol Diagn Ther Date: 2017-04 Impact factor: 4.074
Authors: Yu Imamura; Paul Lochhead; Mai Yamauchi; Aya Kuchiba; Zhi Rong Qian; Xiaoyun Liao; Reiko Nishihara; Seungyoun Jung; Kana Wu; Katsuhiko Nosho; Yaoyu E Wang; Shouyong Peng; Adam J Bass; Kevin M Haigis; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Shuji Ogino Journal: Mol Cancer Date: 2014-05-31 Impact factor: 27.401